Dopamine receptor (D1-D5) (DRD)

Dopamine receptors are a class of G protein-coupled receptors (GPCRs) that mediate the physiological actions of the neurotransmitter dopamine in the central nervous system and peripheral tissues (StatPearls, 2023). They are divided into two main subfamilies: the D1-like receptors (D1 and D5), which stimulate adenylyl cyclase via Gs proteins, and the D2-like receptors (D2, D3, and D4), which inhibit adenylyl cyclase via Gi/o proteins (UniProt, 2024). These receptors play a fundamental role in regulating motor function, reward-seeking behavior, cognition, and neuroendocrine secretion (NIH, 2023). Dysregulation of the dopaminergic system is central to the pathophysiology of several major disorders, including Parkinson's disease, schizophrenia, and attention-deficit hyperactivity disorder (ADHD) (PubMed, 2022). Pharmacological management often involves the use of dopamine receptor agonists to treat motor deficits or antagonists to alleviate psychotic symptoms (PubChem, 2024). However, targeting these receptors can lead to significant side effects, such as extrapyramidal symptoms or metabolic disturbances, due to their widespread influence on neural circuits (StatPearls, 2023). Understanding the subtype-specific distribution and signaling pathways of these receptors remains a key focus for developing more selective and safer therapeutic agents (NIH, 2023).

Other names

Dopaminergic receptorsD1-like receptorsD2-like receptorsDopamine D1 receptorDopamine D2 receptorDopamine D3 receptorDopamine D4 receptorDopamine D5 receptor

Drugs targeting dopamine receptors primarily act through three mechanisms: agonism, antagonism, or partial agonism. Agonists mimic dopamine to stimulate receptors (primarily D2/D3) to restore motor function in Parkinson's disease (StatPearls, 2023). Antagonists block D2 receptors to reduce overactive dopaminergic signaling in the mesolimbic pathway to treat schizophrenia (PubMed, 2022). Partial agonists act as functional stabilizers, providing agonism in low-dopamine states and antagonism in high-dopamine states (NIH, 2023).